Mga Batayang Estadistika
| CIK | 1671818 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Oncorus, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| August 3, 2023 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39575 Oncorus, Inc. (Exact name of registrant as specified in its |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| July 28, 2023 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2023 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| July 19, 2023 |
ONCORUS, INC. 4 Corporate Drive Andover, MA 01810 (339) 240-3330 RW ONCORUS, INC. 4 Corporate Drive Andover, MA 01810 (339) 240-3330 July 19, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549 Re: Oncorus, Inc. – Request for Withdrawal of Registration Statement on Form S-3 (File No. 333-260718) Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amen |
|
| July 19, 2023 |
As filed with the Securities and Exchange Commission on July 19, 2023 As filed with the Securities and Exchange Commission on July 19, 2023 Registration No. |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2023 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| July 19, 2023 |
As filed with the Securities and Exchange Commission on July 19, 2023 As filed with the Securities and Exchange Commission on July 19, 2023 Registration No. |
|
| July 19, 2023 |
As filed with the Securities and Exchange Commission on July 19, 2023 As filed with the Securities and Exchange Commission on July 19, 2023 Registration No. |
|
| July 19, 2023 |
As filed with the Securities and Exchange Commission on July 19, 2023 As filed with the Securities and Exchange Commission on July 19, 2023 Registration No. |
|
| June 26, 2023 |
Exhibit 99.1 Hilco Streambank Seeks Offers to Acquire Patent Portfolio of Biopharmaceutical Company Oncorus Bids due July 7, 2023 New York, New York, June 26, 2023: Hilco Streambank (www.HilcoStreambank.com), a leading intellectual property advisory firm specializing in the valuation and monetization of intangible assets, announced that it is seeking offers to acquire the intangible and related as |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 23, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| June 12, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 08, 2023 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 06, 2023 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 7, 2023 |
PLAN OF LIQUIDATION AND DISSOLUTION OF ONCORUS, INC. PLAN OF LIQUIDATION AND DISSOLUTION OF ONCORUS, INC. This Plan of Liquidation and Dissolution (the “Plan”) is intended to accomplish the complete liquidation and dissolution Oncorus, Inc., a Delaware corporation (the “Company”), in accordance with Section 281(b) of the General Corporation Law of the State of Delaware (the “DGCL”). 1. Approval of Plan. The Board of Directors of the Company (the “Bo |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2023 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 1, 2023 |
Oncorus Announces Workforce Reduction Plan Exhibit 99.1 Oncorus Announces Workforce Reduction Plan Andover, Mass., June 1, 2023 – Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that, in response to challenges associated with raising additional capital and pursuing strategic alternatives to secure addition |
|
| May 22, 2023 |
Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates Exhibit 99.1 Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates • IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding • Ended the quarter with $45.0 million in cash, cash equivalents and investments Andover, Mass., May 22, 2023 – Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously ad |
|
| May 22, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39575 ONCORUS, INC. |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NT 10-Q 1 formnt10-q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER: 001-39575 CUSIP NUMBER: 68236R103 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Tran |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 02, 2023 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2023 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3 |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39575 G ONCORUS, INC. |
|
| March 24, 2023 |
As filed with the Securities and Exchange Commission on March 24, 2023 As filed with the Securities and Exchange Commission on March 24, 2023 Registration No. |
|
| March 24, 2023 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| March 24, 2023 |
Exhibit 10.29 FOURTH AMENDMENT TO LEASE (Innovation Park) THIS FOURTH AMENDMENT TO LEASE (“Fourth Amendment”) is made and entered into as of the 14th day of December, 2022 (“Effective Date”), by and between IQHQ‑4 CORPORATE, LLC, a Delaware limited liability company (“Landlord”) and ONCORUS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant entered into that certain Lease Ag |
|
| March 24, 2023 |
Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates Exhibit 99.1 Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates • Reprioritized product portfolio to focus on IV-administered, self-amplifying RNA medicines • On track to submit IND for ONCR-021 in mid-2023 • Preclinical data featured in Nature Communications support self-amplifying RNA platform and promise of repeat IV-administration • Ended the quar |
|
| March 24, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Oncorus, Inc. (Exact name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity 2020 Equity Incen |
|
| March 24, 2023 |
License Agreement by and between the registrant and NOF Corporation, dated as of October 31, 2022 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| March 24, 2023 |
Exhibit 10.13 ONCORUS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”), effective as of February 11, 2022 (the “Effective Date”), is made by and among Oncorus, Inc., a Delaware corporation (the “Company”) and John Goldberg, M.D. (the “Executive” and, together with the Company, the “Parties”), and amends and restates in its entirety th |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| February 14, 2023 |
ONCR / Oncorus Inc / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm233236-22sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3)* Oncorus, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (the “Shares”) (Title of |
|
| February 13, 2023 |
ONCR / Oncorus Inc / CHI Advisors LLC - CHI ADVISORS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Oncorus, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68236R 103 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 2, 2023 |
ONCR / Oncorus Inc / Arkin Moshe - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Oncorus, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 68236R103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| January 19, 2023 |
ONCR / Oncorus Inc / Flynn James E Activist Investment SC 13D/A 1 e618206sc13da-oncorus.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. 4)* Oncorus, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68236R103 (CUSIP Number) |
|
| January 17, 2023 |
ONCR / Oncorus Inc / Flynn James E Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. 3)* Oncorus, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68236R103 (CUSIP Number) David Clark Elliot Press Deerfield Ma |
|
| January 3, 2023 |
ONCR / Oncorus Inc / Flynn James E Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. 2)* Oncorus, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68236R103 (CUSIP Number) David Clark Elliot Press Deerfield Ma |
|
| December 22, 2022 |
ONCR / Oncorus Inc / Flynn James E Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13D-2(a) (Amendment No. 1)* Oncorus, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68236R103 (CUSIP Number) David Clark Elliot Press Deerfield Ma |
|
| November 30, 2022 |
Exhibit 99.1 Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer – Company now focused on the development of ONCR-021, Oncorus’ lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program remains on track for IND submission in mid-2023 - – Phase 1 clinical trial of ONCR-177 in patients wi |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 2, 2022 |
Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates Exhibit 99.1 Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates ? Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in the fourth quarter of 2022 ? On track to submit IND for ONCR-021 in mid-2023 ? Completed construction phase of GMP-compliant manufacturing facility in Andover, MA ? Ended the quarter with $8 |
|
| November 2, 2022 |
Exhibit 10.2 THIRD AMENDMENT TO LEASE (Innovation Park) THIS THIRD AMENDMENT TO LEASE (?Third Amendment?) is made and entered into as of the 26th day of September, 2022 (?Effective Date?), by and between IQHQ-4 CORPORATE, LLC, a Delaware limited liability company (?Landlord?) and ONCORUS, INC., a Delaware corporation (?Tenant?). R E C I T A L S: A. Landlord and Tenant entered into that certain Lea |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39575 ONCORUS, INC. |
|
| November 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2022 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 1, 2022 |
ONCR / Oncorus Inc / K2 HealthVentures Equity Trust LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Oncorus, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 68236R103 (CUSIP Number) April 1, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| November 1, 2022 |
EX-99.1 EXHIBIT 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the common stock, $0.0001 par value per share, of Oncorus, Inc., a Delaware corporation, and further agree that this Joint |
|
| September 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2022 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| September 14, 2022 |
Exhibit 10.1 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this ?Amendment?) is entered into as of this 13th day of September, 2022, by and between BMR-HAMPSHIRE LLC, a Delaware limited liability company (?Landlord?), and ONCORUS, INC., a Delaware corporation (?Tenant?). RECITALS A. WHEREAS, Landlord and Tenant are parties to that certain Lease dated as of May 10, 2016 as amended by th |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2022 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 4, 2022 |
Employment Agreement by and between the registrant and Richard Wanstall, dated as of May 10, 2022 Exhibit 10.2 ONCORUS, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), effective as of May 10, 2022 (the ?Effective Date?), is made by and among Oncorus, Inc., a Delaware corporation (the ?Company?) and Rick Wanstall (the ?Executive? and, together with the Company, the ?Parties?). WHEREAS, the Company desires to employ Executive as its Chief Financial Officer, and to enter in |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39575 ONCORUS, INC. |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2022 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 4, 2022 |
Oncorus Reports Second Quarter 2022 Financial Results and Provides Business Updates Exhibit 99.1 Oncorus Reports Second Quarter 2022 Financial Results and Provides Business Updates ? Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in second half of 2022 ? Company remains on track to submit IND for ONCR-021 in mid-2023 ? Ended quarter with $100.2 million in cash and cash equivalents to support next-generation viral immun |
|
| June 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 23, 2022 |
Exhibit 99.1 Oncorus Appoints Douglas Fambrough to Board of Directors - Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and financing- CAMBRIDGE, Mass., June 23, 2022 ? Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Douglas M |
|
| May 13, 2022 |
DEF 14A 1 oncrdef14a-2022prox.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2022 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 4, 2022 |
Oncorus Reports First Quarter 2022 Financial Results and Provides Business Updates Exhibit 99.1 Oncorus Reports First Quarter 2022 Financial Results and Provides Business Updates ? Additional clinical data from ONCR-177 surface lesion monotherapy expansion and combination expansion cohorts expected in second half of 2022 ? Preclinical data presented for ONCR-021 and ONCR-788 at AACR Annual Meeting supports selectively self-amplifying vRNA/LNP immunotherapy platform; on track to |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39575 ONCORUS, INC. |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3 |
|
| April 29, 2022 |
Employment Agreement by and between the registrant and John McCabe, dated as of October 6, 2020. DocuSign Envelope ID: 3D3FBE8E-6F14-4EB0-A8F6-096964983446 Exhibit 10.13 ONCORUS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the ?Agreement?), effective as of the IPO Closing Date (the ?Effective Date?), is made by and among Oncorus, Inc., a Delaware corporation (the ?Company?) and John McCabe (?Executive? and, together with the Company, the ?Par |
|
| April 29, 2022 |
Consulting Agreement by and between the registrant and John McCabe, dated as of April 1, 2022. Exhibit 10.14 ONCORUS, INC. CONSULTING AGREEMENT Effective Date: April 1, 2022 This Consulting Agreement (the ?Agreement?) is made as of the Effective Date set forth above by and between Oncorus, Inc. (?Client?) and John McCabe (?Consultant?). 1. Engagement of Services. Client may issue Project Assignments to Consultant in the form attached to this Agreement as Exhibit A (each, a ?Project Assignme |
|
| April 5, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| April 5, 2022 |
Exhibit 99.1 Oncorus Announces Debt Capital Facility with K2 HealthVentures with $20 Million Funded at Closing, Relocation of Corporate Headquarters and Extension of Cash Runway -Multiple tranche debt financing agreement provides Oncorus with access to up to $45 million- -Use of proceeds intended to support completion of a GMP-compliant manufacturing facility in Andover, MA and the clinical develo |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 5, 2022 |
Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY U.S. STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM A |
|
| March 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 9, 2022 |
Exhibit 10.10 January 25, 2022 Mitchell H. Finer, Ph.D. c/o MPM Capital 450 Kendall Street Cambridge, MA 02142 Re: Transition to Board Chairman Dear Dr. Finer: This letter memorializes the understanding between you, Mitchell H. Finer, Ph.D., and Oncorus, Inc. (the ?Company?) as of the date hereof (the ?Effective Date?) with respect to your transition from the role of Executive Chairman of the Comp |
|
| March 9, 2022 |
Exhibit 10.25 SECOND AMENDMENT TO LEASE (Innovation Park) THIS SECOND AMENDMENT TO LEASE (?Second Amendment?) is made and entered into as of the 17th day of November, 2021, by and between IQHQ?4 CORPORATE, LLC, a Delaware limited liability company (?Landlord?) and ONCORUS, INC., a Delaware corporation (?Tenant?). R E C I T A L S: A. Landlord and Tenant entered into that certain Lease Agreement ent |
|
| March 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 09, 2022 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 9, 2022 |
As filed with the Securities and Exchange Commission on March 9, 2022 As filed with the Securities and Exchange Commission on March 9, 2022 Registration No. |
|
| March 9, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Oncorus, Inc. (Exact name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity 2020 Equity Incen |
|
| March 9, 2022 |
Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates ? Data presented from ongoing Phase 1 clinical trial of ONCR-177 in multiple solid tumor indications at RP2D at SITC 2021 and preclinical studies of ONCR-GBM targeting brain cancer at IOVC 2021 ? Signed exclusive licensing agreement with Gaeta Therapeutics for use of locally delivered IL-12 via oncoly |
|
| March 9, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39575 G ONCORUS, INC. |
|
| February 15, 2022 |
ONCR / Oncorus Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Oncorus, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68236R 103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 15, 2022 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| February 14, 2022 |
ONCR / Oncorus Inc / CITADEL ADVISORS LLC - ONCORUS, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Oncorus, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (the “Shares”) (Title of Class of Securities) 68236R103 (CUSIP Num |
|
| February 11, 2022 |
ONCR / Oncorus Inc / CHI Advisors LLC - CHI ADVISORS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Oncorus, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68236R 103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| January 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2022 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 10, 2022 |
Corporate Presentation January 2022 Viral Immunotherapies for Cancer NASDAQ: ONCR Corporate Presentation January 2022 Viral Immunotherapies for Cancer NASDAQ: ONCR This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect the current beliefs, expectations and assumptions of Oncorus, Inc. |
|
| December 2, 2021 |
ONCR / Oncorus Inc / Arkin Moshe - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Oncorus, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 68236R103 (CUSIP Number) November 22, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| November 19, 2021 |
Exhibit 99.1 The registrant is filing this Exhibit 99.1 for the purpose of incorporating the information set forth herein by reference into the registration statement on Form S-3 (File No. 333-260718) that was filed by the registrant with the Securities and Exchange Commission on November 3, 2021 and became effective November 12, 2021. The following table sets forth the estimated costs and expense |
|
| November 19, 2021 |
Exhibit 10.1 OPEN MARKET SALE AGREEMENT November 19, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Oncorus, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s common stock, pa |
|
| November 19, 2021 |
Up to $50,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-260718 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 12, 2021) Up to $50,000,000 Common Stock We entered into an Open Market Sale AgreementSM, or the Sales Agreement, with Jefferies LLC, or Jefferies, on November 19, 2021, relating to the sale of shares of our common stock, $0.0001 par value per share, offered by this pr |
|
| November 19, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2021 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 12, 2021 |
Exhibit 99.1 Oncorus Reports Initial Safety, Tolerability, Immune Activation and Positive Clinical Response Data from its Ongoing Phase 1 Clinical Study of ONCR-177, its Lead Viral Immunotherapy Candidate, at SITC 2021 ? ONCR-177 was well tolerated with no dose-limiting toxicities in the surface lesion dose escalation part of the first-in-human study in heavily pretreated patients with advanced, i |
|
| November 10, 2021 |
Oncorus, Inc. 50 Hampshire Street, Suite 401 Cambridge, Massachusetts 02139 Oncorus, Inc. 50 Hampshire Street, Suite 401 Cambridge, Massachusetts 02139 November 10, 2021 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jordan Nimitz Re: Oncorus, Inc. Registration Statement on Form S-3 (File No. 333-260718) Request for Acceleration of Effective Date Ladies & Gentlemen: In accordance w |
|
| November 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2021 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 9, 2021 |
Exhibit 99.1 Oncorus Announces Details of Upcoming ONCR-177 Phase 1 Initial Clinical Data Presentation at the Society for Immunotherapy of Cancer?s (SITC) 2021 Annual Meeting - Company to host conference call and webcast on Friday, November 12, 2021 at 8:30 a.m. ET - CAMBRIDGE, Mass., November 9, 2021 ? Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapy company focused on driving innovation to tr |
|
| November 3, 2021 |
Oncorus Reports Third Quarter 2021 Financial Results and Provides Business Updates Exhibit 99.1 Oncorus Reports Third Quarter 2021 Financial Results and Provides Business Updates ? To report initial data from ongoing Phase 1 clinical trial of lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate, ONCR-177, in multiple solid tumor indications at the upcoming Society for Immunotherapy of Cancer?s (SITC) 36th Annual Meeting on November 12th ? Completed Pre-IND me |
|
| November 3, 2021 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.9 ONCORUS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AgREEMENT DATED AS OF ONCORUS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between Oncorus, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the laws of [?] a |
|
| November 3, 2021 |
As filed with the Securities and Exchange Commission on November 3, 2021 Table of Contents As filed with the Securities and Exchange Commission on November 3, 2021 Registration No. |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39575 ONCORUS, INC. |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2021 ONCORUS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 3, 2021 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.10 ONCORUS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF ONCORUS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between Oncorus, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the laws of [?] |
|
| November 3, 2021 |
Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.8 ONCORUS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF ONCORUS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between ONCORUS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the laws of [?] and having |
|
| November 3, 2021 |
Exhibit 4.6 Oncorus, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Section 2.03 |
|
| November 3, 2021 |
Exhibit 10.1 AMENDED AND RESTATED FIRST AMENDMENT TO LEASE (Innovation Park) THIS AMENDED AND RESTATED FIRST AMENDMENT TO LEASE (?First Amendment?) is made and entered into as of the 25th day of October, 2021, by and between IQHQ-4 CORPORATE, LLC, a Delaware limited liability company (?Landlord?) and ONCORUS, INC., a Delaware corporation (?Tenant?). R E C I T A L S: A. Landlord and Tenant entered |
|
| August 4, 2021 |
Oncorus Reports Second Quarter 2021 Financial Results and Provides Business Highlights Exhibit 99.1 Oncorus Reports Second Quarter 2021 Financial Results and Provides Business Highlights ? Continues to progress Phase 1 clinical trial of ONCR-177, company?s lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate; on track to report initial interim data in 4Q?21 ? Nominated company?s first intravenously (IV) administered Synthetic viral RNA (vRNA) immunotherapy candid |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d109445d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 Oncorus, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporatio |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39575 ONCORUS, INC. |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2021 Oncorus, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction (Commission (IRS Employer of Incorporatio |
|
| July 29, 2021 |
Exhibit 99.1 Oncorus Expands its Board with Appointment of Barbara Yanni ? Former Merck executive brings extensive experience in corporate development, licensing and financial evaluation, and expertise advising clinical stage public biopharmaceutical companies ? CAMBRIDGE, Mass. ? July 29, 2021 ? Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation vi |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 Oncorus, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 21, 2021 |
Exhibit 99.1 Oncorus Appoints Eric Rubin, M.D. to its Board of Directors ? Renowned academic and industry leader brings deep expertise in oncology translational research and drug development, including pioneering work at Merck on KEYTRUDA? (pembrolizumab) ? CAMBRIDGE, Mass. ? June 17, 2021 ? Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation viral i |
|
| June 15, 2021 |
Oncorus to Host Investor Day Featuring its IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Platform and Lead Synthetic vRNA Product Candidates ? Virtual event will take place on June 21, 2021 from 1:00 ? 2:30 p. |
|
| June 15, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 Oncorus, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 27, 2021 |
Exhibit 99.1 Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates, ONCR-021 and ONCR-788 ? Pioneering Synthetic vRNA immunotherapies that are composed of self-amplifying vRNA encoding for oncolytic viruses encapsulated within lipid nanoparticles (LNPs) ? Novel approach engineered to produce a living immunostimulatory drug in the form |
|
| May 27, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2021 Oncorus, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39575 ONCORUS, INC. |
|
| May 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 Oncorus, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 4, 2021 |
EX-99.1 2 d356665dex991.htm EX-99.1 Exhibit 99.1 Oncorus Reports First Quarter 2021 Financial Results and Provides Business Highlights — Enrollment continues in Phase 1 clinical trial of lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate ONCR-177; initial interim data expected in 2H’21 — — Company plans to nominate first two intravenously (IV) administered synthetic viral RNA |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 28, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 6, 2021 |
8-K 1 d651248d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2021 Oncorus, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39575 47-3779757 (state or other jurisdiction of incorporatio |
|
| March 23, 2021 |
8-K 1 d102478d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2021 Oncorus, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39575 47-3779757 (state or other jurisdiction of incorporatio |
|
| March 10, 2021 |
Oncorus Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights EX-99.1 2 d54018dex991.htm EX-99.1 Exhibit 99.1 Oncorus Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights • 2020 marked year of notable progress for Oncorus. Key highlights included: • Transitioned to clinical-stage company with initiation of Phase 1 clinical trial of lead viral immunotherapy candidate, ONCR-177, for the treatment of solid tumors • Announ |
|
| March 10, 2021 |
Description of Registrant’s Securities. EX-4.4 2 oncr-ex44715.htm EX-4.4 Exhibit 4.4 DESCRIPTION OF ONCORUS, INC. COMMON STOCK The following description of the common stock of Oncorus, Inc., or the Company, is a summary and does not purport to be complete. This summary is qualified in its entirety by reference to the provisions of the Delaware General Corporation Law, or the DGCL, and the complete text of the Company’s amended and resta |
|
| March 10, 2021 |
As filed with the Securities and Exchange Commission on March 10, 2021 Registration No. |
|
| March 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 Oncorus, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39575 47-3779757 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39575 ONCORUS, INC. ( |
|
| March 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Oncorus, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68236R 103 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 16, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Oncorus, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68236R 103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G*/ (Rule 13d-102) Under the Securities Exchange Act of 1934 (Amendment No. 1)* Oncorus, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 68236R103 (CUSIP Number) December 31, 2020 Date of Event Which Requires Filing of the Statement Check the appropriate box to designat |
|
| February 16, 2021 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G/A filed herewith (and any amendments thereto), relating to the common stock of Oncorus, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersign |
|
| February 12, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-252896 PROSPECTUS 3,000,000 Shares Common Stock We are offering 3,000,000 shares of common stock. Our common stock is listed on The Nasdaq Global Market under the symbol ?ONCR.? The closing price of our common stock on February 11, 2021, as reported by The Nasdaq Global Market, was $20.97 per share. We are an ?emerging growth |
|
| February 9, 2021 |
Employment Agreement by and between the registrant and Steve Harbin, dated as of December 7, 2020 EX-10.12 Exhibit 10.12 ONCORUS, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), which shall be effective as of December 7, 2020 subject to the appointment by the Company’s Board of Directors (the “Board”) of the Executive as the Company’s Chief Operating Officer and Chief of Staff (the “Effective Date”), is made by and among Oncorus, Inc., a Delaware corporation (the “Compan |
|
| February 9, 2021 |
Jefferies LLC 520 Madison Avenue New York, New York 10022 Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 February 9, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Oncorus, Inc. Acceleration Request |
|
| February 9, 2021 |
Lease Agreement by and between IQHQ-4 Corporate, LLC and the Company, dated as of December 29, 2020. Exhibit 10.21 LEASE AGREEMENT BY AND BETWEEN IQHQ– 4 CORPORATE, LLC, a Delaware limited liability company, AS LANDLORD, AND ONCORUS, INC., a Delaware corporation, AS TENANT First Floors of Pod 4 and Pod 5 Plus a Portion of Ground Floor of Pod 5 Innovation Park TABLE OF CONTENTS Page ARTICLE 1 BASIC LEASE PROVISIONS 1 ARTICLE 2 TERM/PREMISES 5 ARTICLE 3 RENTAL 6 (a) Basic Rental 6 (b) Increase |
|
| February 9, 2021 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on February 9, 2021. |
|
| February 9, 2021 |
Form of Underwriting Agreement. EX-1.1 2 d54295dex11.htm EX-1.1 Exhibit 1.1 [•] Shares Oncorus, Inc. UNDERWRITING AGREEMENT [•], 2021 JEFFERIES LLC EVERCORE GROUP L.L.C. PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o EVERCORE GROUP L.L.C. 55 East 52nd Street New York, New York 10055 c/o PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall |
|
| February 9, 2021 |
ONCORUS, INC. 50 Hampshire Street, Suite 401 Cambridge, Massachusetts 02139 February 9, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Nudrat Salik Mr. Daniel Gordon Ms. Abby Adams Ms. Irene Paik RE: Oncorus, Inc. Registration Statement on Form S-1 File No. 333-252896 Ladies and Gentlemen: Oncorus, Inc. (the ?Registr |
|
| January 28, 2021 |
ONCORUS, INC. EMPLOYMENT AGREEMENT EX-10.12 Exhibit 10.12 ONCORUS, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), which shall be effective as of December 7, 2020 subject to the appointment by the Company’s Board of Directors (the “Board”) of the Executive as the Company’s Chief Operating Officer and Chief of Staff (the “Effective Date”), is made by and among Oncorus, Inc., a Delaware corporation (the “Compan |
|
| January 28, 2021 |
EX-10.21 Exhibit 10.21 LEASE AGREEMENT BY AND BETWEEN IQHQ– 4 CORPORATE, LLC, a Delaware limited liability company, AS LANDLORD, AND ONCORUS, INC., a Delaware corporation, AS TENANT First Floors of Pod 4 and Pod 5 Plus a Portion of Ground Floor of Pod 5 Innovation Park TABLE OF CONTENTS Page ARTICLE 1 BASIC LEASE PROVISIONS 1 ARTICLE 2 TERM/PREMISES 5 ARTICLE 3 RENTAL 6 (a) Basic Rental 6 (b) |
|
| January 28, 2021 |
DRS Table of Contents Confidential Treatment Requested by Oncorus, Inc. Pursuant To 17 C.F.R. Section 200.83 As confidentially submitted to the Securities and Exchange Commission on January 27, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains confidential. Registration Statement No. 333- UNITED STATES |
|
| January 4, 2021 |
EX-99.1 Exhibit 99.1 Oncorus to Build GMP Viral Immunotherapy Clinical Manufacturing Facility in Andover, Mass. — 88,000 square foot state-of-the-art facility will support Oncorus’ advancing, multi-product pipeline of intratumorally and intravenously administered viral immunotherapies – — Initial phase of site buildout anticipated to be completed in fourth quarter 2021 — — Company anticipates site |
|
| January 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2020 Oncorus, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39575 47-3779757 (state or other jurisdiction of incorporation) (Commission File Nu |
|
| December 14, 2020 |
EX-99.1 Exhibit 99.1 Oncorus Appoints Scott Canute to its Board of Directors — Former Genzyme and Lilly executive brings broad industry expertise as Oncorus advances its viral immunotherapies pipeline and plans strategic operations and manufacturing scale-up — CAMBRIDGE, Mass. – December 14, 2020 — Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation |
|
| December 14, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2020 Oncorus, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39575 47-3779757 (state or other jurisdiction of incorporation) (Commission Fil |
|
| December 7, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2020 Oncorus, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39575 47-3779757 (state or other jurisdiction of incorporation) (Commission File |
|
| December 7, 2020 |
EX-99.1 Exhibit 99.1 Oncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff — Former Moderna executive and industry veteran brings diverse operational expertise as Oncorus plans buildout of its manufacturing capabilities to support its viral immunotherapy pipeline — CAMBRIDGE, Mass. – December 7, 2020 — Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company d |
|
| November 12, 2020 |
EX-10.1 Exhibit 10.1 ONCORUS, INC. 2020 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: SEPTEMBER 15, 2020 APPROVED BY THE STOCKHOLDERS: SEPTEMBER 25, 2020 TABLE OF CONTENTS Page 1. General 1 2. Shares Subject to the Plan 1 3. Eligibility and Limitations 2 4. Options and Stock Appreciation Rights 3 5. Awards Other Than Options and Stock Appreciation Rights 7 6. Adjustments upon Changes in |
|
| November 12, 2020 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39575 ONCORUS, INC. |
|
| November 12, 2020 |
2020 Employee Stock Purchase Plan. EX-10.2 Exhibit 10.2 ONCORUS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: SEPTEMBER 15, 2020 APPROVED BY THE STOCKHOLDERS: SEPTEMBER 25, 2020 IPO DATE: OCTOBER 1, 2020 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2020 Oncorus, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39575 47-3779757 (state or other jurisdiction of incorporation) (Commission Fil |
|
| November 12, 2020 |
EX-99.1 Exhibit 99.1 Oncorus Reports Third Quarter 2020 Financial Results and Provides Business Highlights — Received $98.4 million in aggregate gross proceeds in October from initial public offering — — Initiated Phase 1 clinical trial of lead viral immunotherapy candidate, ONCR-177, for the treatment of solid tumors — — Announced clinical trial collaboration with Merck to evaluate combination of |
|
| October 21, 2020 |
ONCR / Oncorus, Inc. / MPM BioVentures 2014, L.P. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Oncorus, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68236R103 (CUSIP Number) Ansbert Gadicke MPM Asset Management 450 Kendall Street Cambridge, MA 01242 Telephone: (617) 425-9200 (Name, Address and Telephone Number of Person |
|
| October 21, 2020 |
EX-99.C Exhibit C Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Oncorus, Inc. is filed on behalf of each of the undersigned. Date: October 20, 2020 MPM BIOVENTURES 2014, L.P. By: MPM BioVentures 2014 GP LLC, its General Partner By: |
|
| October 16, 2020 |
ONCR / Oncorus, Inc. / Flynn James E Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. )* Oncorus, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68236R103 (CUSIP Number) David Clark Elliot Press Deerfield Man |
|
| October 16, 2020 |
Joint Filing Agreement dated as of October 16, 2020 by and among the Reporting Persons.* Exhibit 99.1 The undersigned agree that this Schedule 13D, and all amendments thereto, relating to the Common Stock of Oncorus, Inc. shall be filed on behalf of the undersigned. DEERFIELD MGMT III, L.P. By: J.E. Flynn Capital III, LLC, General Partner By: /s/ Jonathan Isler Name: Jonathan Isler Title: Attorney-in-Fact DEERFIELD PRIVATE DESIGN FUND III, L.P. By: Deerfield Mgmt III, L.P., General Pa |
|
| October 13, 2020 |
ONCR / Oncorus, Inc. / CITADEL ADVISORS LLC - SC 13G Passive Investment SC 13G 1 tm2033088d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G*/ (Rule 13d-102) Oncorus, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 68236R103 (CUSIP Number) October 2, 2020 Date of Event Which Requires Filing of the Statement Check the appropriate box to designate the rule pursuant to whi |
|
| October 13, 2020 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Oncorus, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned |
|
| October 9, 2020 |
S-8 As filed with the Securities and Exchange Commission on October 9, 2020 Registration No. |
|
| October 9, 2020 |
EX-4.9 2 d42675dex49.htm EX-4.9 Exhibit 4.9 ONCORUS, INC. 2020 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Oncorus, Inc. (the “Company”), pursuant to its 2020 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject |
|
| October 6, 2020 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ONCORUS, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meeting. 1 Section 6. Special Meetings. 5 Section 7. Notice of Meeti |
|
| October 6, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2020 Oncorus, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39575 47-3779757 (state or other jurisdiction of incorporation) (Commission File |
|
| October 6, 2020 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ONCORUS, INC. Theodore Ashburn, M.D., Ph.D. hereby certifies that: ONE: The original date of filing the original Certificate of Incorporation of this company with the Secretary of State of the State of Delaware was April 1, 2015. TWO: He is the duly elected and acting Chief Executive Officer and President of ONCORUS, INC., a D |
|
| October 2, 2020 |
424B4 Table of Contents Pursuant to Rule 424(b)(4) Registration No. 333-248757 PROSPECTUS 5,800,000 Shares Common Stock We are offering 5,800,000 shares of common stock. This is our initial public offering of our common stock. Prior to this offering, there has been no public market for our shares. The initial public offering price is $15.00 per share. Our common stock has been approved for listing |
|
| September 29, 2020 |
CORRESP Jefferies LLC 520 Madison Avenue New York, New York 10022 Evercore Group L. |
|
| September 29, 2020 |
CORRESP ONCORUS, INC. 50 Hampshire Street, Suite 401 Cambridge, Massachusetts 02139 September 29, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Nudrat Salik Mr. Daniel Gordon Ms. Abby Adams Ms. Irene Paik RE: Oncorus, Inc. Registration Statement on Form S-1 File No. 333-248757 Ladies and Gentlemen: Oncorus, Inc. (th |
|
| September 29, 2020 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(B) OR (G) OF THE SECURITIES EXCHANGE ACT OF 1934 Oncorus, Inc. |
|
| September 28, 2020 |
Form of Stock Option Grant Notice and Option Agreement for the 2020 Equity Incentive Plan. EX-10.6 Exhibit 10.6 ONCORUS, INC. 2020 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE Oncorus, Inc. (the “Company”), pursuant to its 2020 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice |
|
| September 28, 2020 |
Form of Amended and Restated Bylaws, to be in effect upon closing of this offering. EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF ONCORUS, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meeting. 1 Section 6. Special Meetings. 5 Section 7. Notice of Meeti |
|
| September 28, 2020 |
EX-3.3 Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ONCORUS, INC. Theodore Ashburn, M.D., Ph.D. hereby certifies that: ONE: The original date of filing the original Certificate of Incorporation of this company with the Secretary of State of the State of Delaware was April 1, 2015. TWO: He is the duly elected and acting Chief Executive Officer and President of ONCORUS, INC., a D |
|
| September 28, 2020 |
EX-10.21 Exhibit 10.21 ONCORUS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”), effective as of the IPO Closing Date (the “Effective Date”), is made by and among Oncorus, Inc., a Delaware corporation (the “Company”) and John McCabe (“Executive” and, together with the Company, the “Parties”), and amends and restates in its entirety th |
|
| September 28, 2020 |
EX-10.20 Exhibit 10.20 ONCORUS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”), effective as of the IPO Closing Date (the “Effective Date”), is made by and among Oncorus, Inc., a Delaware corporation (the “Company”) and Ted T. Ashburn, M.D., Ph.D. (“Executive” and, together with the Company, the “Parties”), and amends and restates in |
|
| September 28, 2020 |
2020 Employee Stock Purchase Plan. EX-10.7 Exhibit 10.7 ONCORUS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: SEPTEMBER 15, 2020 APPROVED BY THE STOCKHOLDERS: SEPTEMBER 25, 2020 IPO DATE: , 2020 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan |
|
| September 28, 2020 |
Fifth Amended and Restated Certificate of Incorporation, as amended and as presently in effect. EX-3.1 Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF Oncorus, Inc. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Oncorus, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. That the name |
|
| September 28, 2020 |
EX-10.22 Exhibit 10.22 ONCORUS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”), effective as of the IPO Closing Date (the “Effective Date”), is made by and among Oncorus, Inc., a Delaware corporation (the “Company”) and Christophe Queva (“Executive” and, together with the Company, the “Parties”), and amends and restates in its entire |
|
| September 28, 2020 |
EX-1.1 Exhibit 1.1 [●] Shares Oncorus, Inc. UNDERWRITING AGREEMENT [●], 2020 JEFFERIES LLC EVERCORE GROUP L.L.C. PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o EVERCORE GROUP L.L.C. 55 East 52nd Street New York, New York 10055 c/o PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55 |
|
| September 28, 2020 |
Form of Common Stock Certificate. EX-4.2 Exhibit 4.2 .ZQ CERT# COY|CLS RGSTRY ACCT# TRANSTYPE RUN# TRANS# COMMON STOCK PAR VALUE $0.0001 COMMON STOCK Certificate Number ZQ00000000 THIS CERTIFIES THAT ONCORUS, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE ** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. |
|
| September 28, 2020 |
EX-10.5 Exhibit 10.5 ONCORUS, INC. 2020 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: SEPTEMBER 15, 2020 APPROVED BY THE STOCKHOLDERS: SEPTEMBER 25, 2020 IPO DATE: , 2020 TABLE OF CONTENTS Page 1. General 1 2. Shares Subject to the Plan 1 3. Eligibility and Limitations 2 4. Options and Stock Appreciation Rights 3 5. Awards Other Than Options and Stock Appreciation Rights 7 6. Adjustment |
|
| September 28, 2020 |
CORRESP Marc A. Recht VIA EDGAR + 1 617 937 2316 [email protected] September 28, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Nudrat Salik Mr. Daniel Gordon Ms. Abby Adams Ms. Irene Paik Re: Oncorus, Inc. Registration Statement on Form S-1 Filed September 11, 2020 File No. 333-248757 Ladies |
|
| September 28, 2020 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on September 28, 2020. |
|
| September 16, 2020 |
CORRESP Marc A. Recht +1 617 937 2316 [email protected] *FOIA Confidential Treatment Request* Confidential Treatment Requested by Oncorus, Inc. in connection with Registration Statement on Form S-1 (File No. 333-248757) September 16, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Nudrat Salik |
|
| September 11, 2020 |
EX-10.9 Exhibit 10.9 July 25, 2019 John P. McCabe, CPA, MBA Dear John: On behalf of Oncorus, Inc., a Delaware corporation (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter is to summarize the terms of your employment with the Company, should you accept our offer. If accepted, this letter shall be held in escrow by the parties and shall become effect |
|
| September 11, 2020 |
EX-10.19 Exhibit 10.19 LEASE by and between BMR-HAMPSHIRE LLC, a Delaware limited liability company and ONCORUS, INC., a Delaware corporation Table of Contents 1. Lease of Premises 1 2. Basic Lease Provisions 2 3. Term 4 4. Possession and Commencement Date 4 5. Condition of Premises 6 6. Rentable Area 7 7. Rent 8 8. Rent Adjustments 8 9. Operating Expenses and Laboratory Support Expenses 9 10. Tax |
|
| September 11, 2020 |
Form of Common Stock Warrant Agreement. EX-4.3 Exhibit 4.3 ONCORUS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF ONCORUS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ONCORUS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and |
|
| September 11, 2020 |
EX-10.8 Exhibit 10.8 ONCORUS, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), effective as of July 16, 2018 (the “Effective Date”), is made by and among Oncorus, Inc., a Delaware corporation (the “Company”) and Ted T. Ashburn, M.D., Ph.D. (“Executive” and, together with the Company, the “Parties”). WHEREAS, the Company desires to assure itself of the services of Executive by |
|
| September 11, 2020 |
Form of Indemnification Agreement between the registrant and its directors and officers EX-10.1 Exhibit 10.1 FORM OF INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 20 between Oncorus, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless they are provided with adequate pr |
|
| September 11, 2020 |
Offer Letter by and between the registrant and Christophe Quéva, dated as of August 23, 2017. EX-10.10 Exhibit 10.10 August 23, 2017 Christophe Queva, PhD Dear Christophe: On behalf of Oncorus, Inc., a Delaware corporation (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter is to summarize the terms of your employment with the Company, should you accept our offer: 1. You will be employed to serve on a full-time basis as Chief Scientific Office |
|
| September 11, 2020 |
CORRESP Marc A. Recht + 1 617 937 2316 [email protected] VIA EDGAR September 11, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Nudrat Salik Mr. Daniel Gordon Ms. Abby Adams Ms. Irene Paik Re: Oncorus, Inc. Amendment No. 3 to Draft Registration Statement on Form S-1 Submitted August 26, 2020 CIK No. 0001671818 Ladies |
|
| September 11, 2020 |
EX-10.4 Exhibit 10.4 ONCORUS, INC. 2016 EQUITY INCENTIVE PLAN RESTRICTED STOCK GRANT NOTICE Oncorus, Inc. (“Company”), pursuant to its 2016 Equity Incentive Plan (“Plan”), issues to Participant, in exchange for Participant’s past or future services actually or to be rendered to the Company and such other applicable consideration specified below, the number of shares of Common Stock set forth below |
|
| September 11, 2020 |
EX-10.15 Exhibit 10.15 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. NON-EXCLUSIVE LICENSE AGREEMENT This Non-Exclusive License Agreement for Antibodies (“Agreement”) is made and entered into as of July 7, 2016 (the “Effective Date”) by and between: Th |
|
| September 11, 2020 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on September 11, 2020. |
|
| September 11, 2020 |
EX-10.18 Exhibit 10.18 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. ROYALTY TRANSFER AGREEMENT This Royalty Transfer Agreement (the “Agreement”) is made and entered into as of March 31, 2016 (the “Effective Date”), by and between Oncorus, Inc., a Dela |
|
| September 11, 2020 |
Bylaws, as presently in effect. EX-3.2 Exhibit 3.2 BYLAWS OF ONCORUS, INC. (A DELAWARE CORPORATION) BYLAWS OF ONCORUS, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business |
|
| September 11, 2020 |
EX-10.12 Exhibit 10.12 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AGREEMENT THIS LICENSE AGREEMENT (the “Agreement”) is made effective as of 22 December 2015 (the “Execution Date”) by and between Oncorus, Inc., a Delaware corporation having |
|
| September 11, 2020 |
EX-10.14 Exhibit 10.14 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. BIOMATERIALS LICENSE AGREEMENT This Agreement is made effective the 28th day of September, 2016 (the “Effective Date”), by and between the University of Pittsburgh - Of the Commonweal |
|
| September 11, 2020 |
Fifth Amended and Restated Certificate of Incorporation, as amended and as presently in effect. EX-3.1 Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF Oncorus, Inc. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Oncorus, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. That the name |
|
| September 11, 2020 |
EX-4.1 Exhibit 4.1 ONCORUS, INC. THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 5th day of August, 2019, by and among Oncorus, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and an |
|
| September 11, 2020 |
EX-10.13 Exhibit 10.13 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EXCLUSIVE LICENSE AGREEMENT This Agreement is made and entered into as of the 23 day of March, 2016 (“Effective Date”), by and between the University of Pittsburgh – Of the Commonweal |
|
| September 11, 2020 |
EX-10.17 Exhibit 10.17 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AGREEMENT by and between WuXi Biologics Ireland Limited and Oncorus, Inc. July 25, 2019 LICENSE AGREEMENT This License Agreement (this “Agreement”) dated as of July 25, 2019 ( |
|
| September 11, 2020 |
EX-10.11 Exhibit 10.11 ONCORUS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”), effective as of August 8, 2018, (the “Effective Date”) is made by and among Oncorus, Inc., a Delaware corporation (the “Company”) and Mitchell Finer Ph.D. (“Executive” and, together with the Company, the “Parties”). WHEREAS, the Company has employed Execu |
|
| September 11, 2020 |
EX-10.16 Exhibit 10.16 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AGREEMENT This License Agreement (“Agreement”) made this eleventh day of December, 2018 (the “Effective Date”) by and between Northwestern University, an Illinois corporation |
|
| September 11, 2020 |
2016 Equity Incentive Plan, as amended. EX-10.2 Exhibit 10.2 ONCORUS, INC. 2016 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: March 31, 2016 APPROVED BY THE STOCKHOLDERS: March 31, 2016 TERMINATION DATE: March 31, 2026 1. GENERAL. (a) Eligible Stock Award Recipients. Employees, Directors and Consultants are eligible to receive Stock Awards. (b) Available Stock Awards. The Plan provides for the grant of the following types of |
|
| September 11, 2020 |
EX-10.3 Exhibit 10.3 ONCORUS, INC. STOCK OPTION GRANT NOTICE (2016 EQUITY INCENTIVE PLAN) ONCORUS, INC. (the “Company”), pursuant to its 2016 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this notice (this “Grant Not |
|
| August 26, 2020 |
DRS/A Table of Contents As confidentially submitted to the Securities and Exchange Commission on August 25, 2020. |
|
| August 25, 2020 |
DRSLTR Marc A. Recht + 1 617 937 2316 [email protected] VIA EDGAR August 25, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Nudrat Salik Mr. Daniel Gordon Ms. Abby Adams Ms. Irene Paik Re: Oncorus, Inc. Amendment No. 2 to Draft Registration Statement on Form S-1 Submitted July 29, 2020 CIK No. 0001671818 Ladies and G |
|
| July 29, 2020 |
EX-10.13 Exhibit 10.13 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EXCLUSIVE LICENSE AGREEMENT This Agreement is made and entered into as of the 23 day of March, 2016 (“Effective Date”), by and between the University of Pittsburgh – Of the Commonweal |
|
| July 29, 2020 |
DRS/A Table of Contents As confidentially submitted to the Securities and Exchange Commission on July 29, 2020. |
|
| July 29, 2020 |
ONCORUS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT EX-10.11 Exhibit 10.11 ONCORUS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”), effective as of August 8, 2018, (the “Effective Date”) is made by and among Oncorus, Inc., a Delaware corporation (the “Company”) and Mitchell Finer Ph.D. (“Executive” and, together with the Company, the “Parties”). WHEREAS, the Company has employed Execu |
|
| July 29, 2020 |
ONCORUS, INC. EMPLOYMENT AGREEMENT EX-10.8 Exhibit 10.8 ONCORUS, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), effective as of July 16, 2018 (the “Effective Date”), is made by and among Oncorus, Inc., a Delaware corporation (the “Company”) and Ted T. Ashburn, M.D., Ph.D. (“Executive” and, together with the Company, the “Parties”). WHEREAS, the Company desires to assure itself of the services of Executive by |
|
| July 29, 2020 |
ONCORUS, INC. , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF EX-4.3 Exhibit 4.3 ONCORUS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF ONCORUS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ONCORUS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and |
|
| July 29, 2020 |
FIRST AMENDMENT TO OFFER LETTER EX-10.9 Exhibit 10.9 July 25, 2019 John P. McCabe, CPA, MBA Dear John: On behalf of Oncorus, Inc., a Delaware corporation (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter is to summarize the terms of your employment with the Company, should you accept our offer. If accepted, this letter shall be held in escrow by the parties and shall become effect |
|
| December 20, 2019 |
EX-10.19 Exhibit 10.19 LEASE by and between BMR-HAMPSHIRE LLC, a Delaware limited liability company and ONCORUS, INC., a Delaware corporation Table of Contents 1. Lease of Premises 1 2. Basic Lease Provisions 2 3. Term 4 4. Possession and Commencement Date 4 5. Condition of Premises 6 6. Rentable Area 7 7. Rent 8 8. Rent Adjustments 8 9. Operating Expenses and Laboratory Support Expenses 9 10. Tax |
|
| December 20, 2019 |
ONCORUS, INC. THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT EX-4.1 Exhibit 4.1 ONCORUS, INC. THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 5th day of August, 2019, by and among Oncorus, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and an |
|
| December 20, 2019 |
BYLAWS ONCORUS, INC. (A DELAWARE CORPORATION) EX-3.2 Exhibit 3.2 BYLAWS OF ONCORUS, INC. (A DELAWARE CORPORATION) BYLAWS OF ONCORUS, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business |
|
| December 20, 2019 |
EX-3.1 Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF Oncorus, Inc. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Oncorus, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. That the name |
|
| December 20, 2019 |
DRS/A Table of Contents As confidentially submitted to the Securities and Exchange Commission on December 20, 2019. |
|
| December 20, 2019 |
FORM OF INDEMNIFICATION AGREEMENT EX-10.1 Exhibit 10.1 FORM OF INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 20 between Oncorus, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless they are provided with adequate pr |
|
| December 20, 2019 |
DRSLTR VIA EDGAR Marc A. Recht + 1 617 937 2316 [email protected] December 20, 2019 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Nudrat Salik Mr. Daniel Gordon Mr. Paul Fischer Ms. Irene Paik Re: Oncorus, Inc. Draft Registration Statement on Form S-1 Submitted on October 31, 2019 CIK No. 0001671818 Ladies and Gentlemen: |
|
| October 31, 2019 |
NON-EXCLUSIVE LICENSE AGREEMENT EX-10.15 Exhibit 10.15 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. NON-EXCLUSIVE LICENSE AGREEMENT This Non-Exclusive License Agreement for Antibodies (“Agreement”) is made and entered into as of July 7, 2016 (the “Effective Date”) by and between: Th |
|
| October 31, 2019 |
EX-3.1 Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF Oncorus, Inc. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Oncorus, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. That the name |
|
| October 31, 2019 |
ONCORUS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT EX-10.11 Exhibit 10.11 ONCORUS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”), effective as of August 8, 2018, (the “Effective Date”) is made by and among Oncorus, Inc., a Delaware corporation (the “Company”) and Mitchell Finer Ph.D. (“Executive” and, together with the Company, the “Parties”). WHEREAS, the Company has employed Execu |
|
| October 31, 2019 |
APPENDIX A Payments Subject to Section 409A EX-10.10 Exhibit 10.10 August 23, 2017 Christophe Queva, PhD Dear Christophe: On behalf of Oncorus, Inc., a Delaware corporation (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter is to summarize the terms of your employment with the Company, should you accept our offer: 1. You will be employed to serve on a full-time basis as Chief Scientific Office |
|
| October 31, 2019 |
EX-10.18 Exhibit 10.18 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. ROYALTY TRANSFER AGREEMENT This Royalty Transfer Agreement (the “Agreement”) is made and entered into as of March 31, 2016 (the “Effective Date”), by and between Oncorus, Inc., a Dela |
|
| October 31, 2019 |
BIOMATERIALS LICENSE AGREEMENT EX-10.14 Exhibit 10.14 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. BIOMATERIALS LICENSE AGREEMENT This Agreement is made effective the 28th day of September, 2016 (the “Effective Date”), by and between the University of Pittsburgh - Of the Commonweal |
|
| October 31, 2019 |
Exhibit 10.16 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AGREEMENT This License Agreement (?Agreement?) made this eleventh day of December, 2018 (the ?Effective Date?) by and between Northwestern University, an Illinois corporation having a |
|
| October 31, 2019 |
LICENSE AGREEMENT by and between WuXi Biologics Ireland Limited Oncorus, Inc. July 25, 2019 EX-10.17 Exhibit 10.17 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AGREEMENT by and between WuXi Biologics Ireland Limited and Oncorus, Inc. July 25, 2019 LICENSE AGREEMENT This License Agreement (this “Agreement”) dated as of July 25, 2019 ( |
|
| October 31, 2019 |
EX-10.13 Exhibit 10.13 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EXCLUSIVE LICENSE AGREEMENT This Agreement is made and entered into as of the 23 day of March, 2016 (“Effective Date”), by and between the University of Pittsburgh – Of the Commonweal |
|
| October 31, 2019 |
APPENDIX A Payments Subject to Section 409A EX-10.9 Exhibit 10.9 September 7, 2018 Dear John: On behalf of Oncorus, Inc., a Delaware corporation (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter is to summarize the terms of your employment with the Company, should you accept our offer: 1. You will be employed to serve on a full-time basis as Senior Vice President, Clinical Development effecti |
|
| October 31, 2019 |
ONCORUS, INC. STOCK OPTION GRANT NOTICE (2016 EQUITY INCENTIVE PLAN) EX-10.3 Exhibit 10.3 ONCORUS, INC. STOCK OPTION GRANT NOTICE (2016 EQUITY INCENTIVE PLAN) ONCORUS, INC. (the “Company”), pursuant to its 2016 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this notice (this “Grant Not |
|
| October 31, 2019 |
EX-10.12 Exhibit 10.12 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AGREEMENT THIS LICENSE AGREEMENT (the “Agreement”) is made effective as of 22 December 2015 (the “Execution Date”) by and between Oncorus, Inc., a Delaware corporation having |
|
| October 31, 2019 |
ONCORUS, INC. 2016 EQUITY INCENTIVE PLAN RESTRICTED STOCK GRANT NOTICE EX-10.4 Exhibit 10.4 ONCORUS, INC. 2016 EQUITY INCENTIVE PLAN RESTRICTED STOCK GRANT NOTICE Oncorus, Inc. (“Company”), pursuant to its 2016 Equity Incentive Plan (“Plan”), issues to Participant, in exchange for Participant’s past or future services actually or to be rendered to the Company and such other applicable consideration specified below, the number of shares of Common Stock set forth below |
|
| October 31, 2019 |
EX-10.2 Exhibit 10.2 ONCORUS, INC. 2016 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: March 31, 2016 APPROVED BY THE STOCKHOLDERS: March 31, 2016 TERMINATION DATE: March 31, 2026 1. GENERAL. (a) Eligible Stock Award Recipients. Employees, Directors and Consultants are eligible to receive Stock Awards. (b) Available Stock Awards. The Plan provides for the grant of the following types of |
|
| October 31, 2019 |
DRS Table of Contents As confidentially submitted to the Securities and Exchange Commission on October 31, 2019. |
